Navigation Links
Microfluidics Promotes Scientific University Research Using Nanotechnology with Innovation Incentives

New Academic Research Collaboration (ARC) program makes cutting-edge nanomaterials processing equipment more accessible and valuable

Newton, MA (PRWEB) May 17, 2010 -- Microfluidics (OTCBB: MFLU), the exclusive global provider of Microfluidizer(R) high shear fluid processors, has initiated a formal collaboration program to further promote the use of nanotechnology in scientific research at the university level. Microfluidizer processors are currently used by hundreds of leading academic institutions to develop breakthrough drug delivery technologies and tailor novel applications for the nutraceutical/food, chemical, energy and cosmetic industries.

University researchers who would like to learn more about the program should visit

Microfluidizer technology is unique in its ability to achieve uniform target particle sizes on the nano-level with fully scalable results from lab to production volumes. The Academic Research Collaboration (ARC) program was created to make superior nanomaterials processing methods more accessible to a wider range of academic initiatives while providing further value to facilitate research and development efforts:

  • Purchasing incentive for qualified universities
  • Complimentary annual “Proof of Concept” testing in the Microfluidics Technology Center
  • Extended warranty by one full year
  • Bonus referral program
  • Upgrade/trade-in credits for certain machines and technologies
  • Courtesy “Lunch n' Learn” on-campus seminars
  • Preferred rental arrangements where applicable
  • Beta site, demonstration and publication opportunities

“Partnering with Microfluidics has enabled us to advance exciting new nanotechnology-based methods for drug delivery, for example, to penetrate the blood brain barrier,” said Mansoor Amiji, Ph.D., Distinguished Professor and Chair of Pharmaceutical Sciences at Northeastern University. “This is the only technology successful thus far in creating decorated drug nanoparticles which deliver benefits to specific parts of the body and, therefore, accomplish more with less drug.”

“As you reduce the particle size of your formulation containing the compound of interest, you increase its surface area, thereby improving bioavailability and efficacy and, as a result, reducing adverse side effects by decreasing the required dose for effectiveness,” explained Prof. Robert Nicolosi, Ph.D., of the Department of Clinical Laboratory & Nutritional Sciences at University of Massachusetts Lowell. “Microfluidics provides an enabling technology which has allowed us to develop novel properties for pharmaceutical, nutraceutical and cosmeceutical applications.”

More than one in every ten Microfluidizer processors sold are to universities – a figure Microfluidics expects to increase over time as the core model for biopharmaceutical R&D continues to evolve. The recently launched LV1 low volume processor, which for the first time brings Microfluidizer-quality processing capabilities to samples as small as 1 ml, is an ideal solution for universities with limited or high value raw materials.

“The importance of academic research to the pharmaceutical industry's drug development strategy cannot be understated, and it's increasing every day,” said Michael C. Ferrara, Microfluidics President and CEO. “More big and mid-size pharmas are seeking to collaborate on vital R&D programs with universities equipped with the latest equipment for nanomaterials processing. From oncology drugs and vaccines, to foods enhanced with nutrients and more efficient cathodes for fuel and solar cells, the line between academic research and industry commercialization has been blurred. By bringing our gold standard nanomaterial processors more actively to the university level, we are able to improve our customers' business lines while supporting the crucial growth and innovation indicative of expert professors and graduate students worldwide.”

In addition, existing collaborations with universities have led to revolutions in what is possible using nanotechnology. Continuous manufacturing via crystallization and chemical reactions using bottom-up Microfluidics Reaction Technology(TM) (MRT), for example, was developed in a partnership between Microfluidics CTO Thomai “Mimi” Panagiotou, Ph.D., and Robert Fisher, Ph.D., of the Chemical Engineering Department at the Massachusetts Institute of Technology.

Said Dr. Fisher, “I was intrigued by the opportunity to work closely with Microfluidics to develop improved drug fabrication techniques that enhance delivery and efficacy, which pharmaceutical firms will find extremely compelling. This includes producing suspensions with the smallest possible particle size that have been functionalized for specific targeting.”

More information on the ARC program can be found on or by contacting Kris Sarajian at (+1) 617.969.5454 x233.

Microfluidics International Corporation (OTC Bulletin Board: MFLU) is the exclusive producer of Microfluidizer® high shear fluid processors for uniform particle size reduction, robust cell disruption and bottom-up nanoparticle creation. Used primarily by pharmaceutical, biotechnology, chemical, cosmetic, nutraceutical/food and energy companies to research, develop and improve products with efficient processes, more than 3,000 Microfluidizer processors are installed at customer sites in 50 countries around the world. The innovative Microfluidics Technology Center, located at the company's headquarters outside Boston, Mass., is staffed by expert engineers with a wide range of nanotechnology and application experience for Proof of Concept and Process Development services.

By producing smaller particle sizes and a more narrow distribution than other technologies, with scaleup from lab to production guaranteed, Microfluidics enables companies to create tiny particles that achieve big results. To learn more,

# # #

Read the full story at

Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved

Related medicine news :

1. New 'Stop Drinking 411' Campaign Promotes Alcohol Recovery and Prevention via Web Social Media
2. New STOP DRINKING 411 Campaign Promotes Alcohol Recovery and Prevention Via Web Social Media
3. AAHFN Promotes Heart Failure Awareness Week Through Webinar
4. UM School of Medicine scientists find new malaria vaccine is safe and promotes immune response in children
5. Father Channels His Grief into Advocacy, Promotes Simple Actions to Make Hospitals Safer for Children
6. BioMed Realty Trust Promotes Matthew G. McDevitt to Executive Vice President, Real Estate
7. Medical Transcription Services and EHR Provider MxSecure Promotes Tim Erkel to VP, Client Services
8. Hearts and Minds Promotes Wellness; African Americans Living with Mental Illness Have Higher Risk for Other Illnesses.
9. Pinstripe Promotes Jill Schwieters to President of Pinstripe Healthcare
10. Scientific exchange program promotes collaborative quality standards for drugs, food ingredients
11. Scientists find key to gene that promotes cancer metastasis
Post Your Comments:
(Date:11/30/2015)... ... , ... According to an article published November 13th by People ... to show her Instagram followers that the praise that they were bestowing on her ... she didn’t “want to mislead any mommy's who just had babies and are stressing,” ...
(Date:11/30/2015)... ... ... A record crowd gathered at the Pennsylvania Biotech Center of Bucks County ... Institute. , The institute, which is the research arm of the Hepatitis B Foundation, ... conference, which focused on ways companies can work to reduce the cost and improve ...
(Date:11/30/2015)... ... November 30, 2015 , ... At Grand Dental PC, their ... setting. , When you have dental problems, you need to turn to a dentist ... diagnose and treat your needs, a friendly dentist who counsels you on the best ...
(Date:11/30/2015)... ... , ... Newly reviewed and approved “NJ Top Dentist”, Dr. Eugene Isola III, ... Medicine in 1935. His father graduated from NYU School of Dentistry in 1965. ... as their commitment and passion to the Practice of Dentistry. Continuing the family ...
(Date:11/30/2015)... ... November 30, 2015 , ... The Foundation ... cancer education and prevention—is joining forces with the award-winning creator and writer of ... on December 7, 2015 at the Union League of Philadelphia. , The ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... , Nov. 30, 2015 Nevro Corp. (NYSE: ... providing innovative evidence-based solutions for the treatment of chronic pain, ... at the U.S. Patent and Trademark Office (USPTO) has denied ... Patent No. 8,359,102 (the ,102 patent).  ... unit of Boston Scientific Corporation filed two petitions challenging the ...
(Date:11/30/2015)... , Nov. 30, 2015 ... the "Orphan Drugs Market 2015-2019" report ... has announced the addition of the "Orphan ... --> Research and Markets ( ... "Orphan Drugs Market 2015-2019" report to their ...
(Date:11/30/2015)... global cell culture market is expected ... bn by 2022 at a CAGR of 7.1% therein. --> ... its 2013 value of US$6.1 bn to US$11.3 bn by 2022 ... Research has announced the release of a new market research study, ... ,Cell Culture Market - Global Industry Analysis, Size, Share, Growth, Trends ...
Breaking Medicine Technology: